Gedea Biotech AB
8
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis
Role: lead
An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
Role: lead
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Role: lead
Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Role: lead
Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Role: lead
A Randomised, Partly-blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Bacterial Vaginosis Compared With an Untreated Control Group
Role: lead
Clinical Performance and Safety of the Gedea Pessary in Adult Women With Bacterial Vaginosis
Role: lead
VVC Sampling Study for Analysis Validation
Role: lead
All 8 trials loaded